230.83

0.14% -0.32

After Hours: 230.75 -0.08 -0.03%

Ascendis Pharma A S (ASND)

Overview News Price History Option Chain Why ASND Down? Discussions Forecast

Ascendis Pharma A S stock is traded at $230.83, with a volume of 891.71K. It is down -0.14% in the last 24 hours and down -2.87% over the past month. Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Previous Close:

$231.15

Open:

$233.6

24h Volume:

891.71K

Relative Volume:

1.41

Market Cap:

$15.14B

Revenue:

$1.01B

Net Income/Loss:

$581.90M

P/E Ratio:

26.01

EPS:

8.8733

Net Cash Flow:

$50.57M

1W Performance:

+7.06%

1M Performance:

-2.87%

6M Performance:

+15.53%

1Y Performance:

+35.22%

1-Day Range:

$230.23

$237.00

1-Week Range:

$216.50

$237.00

52-Week Range:

$160.86

$250.74

Ascendis Pharma A S Stock (ASND) Company Profile

Name

Ascendis Pharma A S

Sector

Healthcare (1104)

Industry

Biotechnology (617)

Phone

Address

Employee

1,189

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ASND's Discussions on Twitter

Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASND Ascendis Pharma A S	230.83	15.16B	1.01B	581.90M	50.57M	8.8733
VRTX Vertex Pharmaceuticals Inc	451.63	116.49B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	609.94	63.73B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.72	55.49B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	278.09	37.75B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	162.99	33.54B	742.00K	-1.37B	-1.07B	-7.0731

Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Initiated	Barclays	Overweight
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Oct-17-25	Initiated	Raymond James	Strong Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
May-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-16-25	Initiated	RBC Capital Mkts	Outperform
Jan-07-25	Initiated	UBS	Buy
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform
Jun-25-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Initiated	Stifel	Buy
Dec-20-23	Initiated	Jefferies	Buy
Jun-14-23	Resumed	Credit Suisse	Neutral
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Aug-30-22	Resumed	Berenberg	Buy
Mar-28-22	Resumed	Wedbush	Outperform
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy
Mar-01-22	Initiated	Citigroup	Buy
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-06-22	Initiated	Cowen	Market Perform
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Mar-20-20	Initiated	Oppenheimer	Outperform
Oct-11-19	Initiated	Morgan Stanley	Overweight
Mar-25-19	Initiated	Evercore ISI	Outperform
Jan-24-19	Initiated	Cantor Fitzgerald	Overweight
Jan-24-19	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-18	Initiated	Stifel	Buy
Apr-02-18	Reiterated	Leerink Partners	Mkt Perform
May-11-17	Initiated	JP Morgan	Overweight
Mar-09-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Feb-09-17	Initiated	Credit Suisse	Outperform
Sep-26-16	Initiated	Wedbush	Outperform

View All

Ascendis Pharma A S Stock (ASND) Latest News

Jun 18, 2026